{"nctId":"NCT00733096","briefTitle":"A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy","startDateStruct":{"date":"2008-08"},"conditions":["Lumbosacral Radiculopathy"],"count":84,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: etanercept"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: methylprednisolone"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: normal saline"]}],"interventions":[{"name":"etanercept","otherNames":[]},{"name":"methylprednisolone","otherNames":[]},{"name":"normal saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Chronic low back pain of radicular origin of \\> 4 weeks but \\< 6 months duration.\n2. Leg pain \\> back pain.\n3. Failure of conservative therapy to include physical and pharmacotherapy.\n4. MRI evidence of a lateral or paracentral herniated disc corresponding to the patient's radicular symptoms.\n\nExclusion Criteria:\n\n1. Uncontrolled coagulopathy.\n2. Pregnancy, which will be ruled out by a urine pregnancy test in women of childbearing age.\n3. Allergy to contrast dye or amide local anesthetics.\n4. Previous epidural steroid injection within last year.\n5. Unstable medical or psychiatric condition (e.g. unstable angina, congestive heart failure or severe depression) that could preclude an optimal treatment response.\n6. Rheumatoid arthritis or spondylarthropathy.\n7. Unstable neurological condition (e.g. multiple sclerosis)\n8. Systemic infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Numerical Rating Leg Pain Score","description":"0-10 pain score. 0= no pain, 10= worst imaginable pain.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":null},{"groupId":"OG001","value":"3.56","spread":null},{"groupId":"OG002","value":"3.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Oswestry Disability Score","description":"0-100%. 0= no disability, 100% is complete disability","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"40.26","spread":null},{"groupId":"OG002","value":"30.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Perceived Effect","description":"Satisfaction. Number of participants with positive perceived global satisfaction.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Medication Reduction","description":"Number of people who reduced medications","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":["Worsening pain","Nonlocal infection","Nonlocal rash"]}}}